First, targeted sequencing (MSK-IMPACT) was used in the ICI-treated COAD cohort to detect somatic mutations, and targeted sequencing provides fewer gene mutations than WES; second, the ICI-treated cohort lacked transcriptomics, copy number variation (CNV), proteomics data and data related to the tumor evolution; therefore, the association between IL1-MT signaling and the prognosis of COAD patients treated with ICIs could not be further explored. This evidence concerns the gene IL1A and colon adenocarcinoma.